{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Lymphomas&page=19", "query": { "condition": "Refractory Lymphomas", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 2322, "total_pages": 233, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Lymphomas&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Lymphomas&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T01:12:18.773Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00079378", "title": "Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "decitabine", "type": "DRUG" }, { "name": "valproic acid", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2004-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-11-15T01:12:18.773Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00079378" }, { "nct_id": "NCT00053989", "title": "NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases", "Fanconi Anemia", "Aplastic Anemia" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "graft-versus-tumor induction therapy", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "4 Years to 75 Years" }, "enrollment_count": 41, "start_date": "2002-01-29", "completion_date": "2018-07-19", "has_results": true, "last_update_posted_date": "2020-02-10", "last_synced_at": "2026-11-15T01:12:18.773Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00053989" }, { "nct_id": "NCT05602597", "title": "HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed or Refractory Lymphoma" ], "interventions": [ { "name": "Itraconazole 200 mg", "type": "DRUG" }, { "name": "Fluconazole 400 mg", "type": "DRUG" }, { "name": "Rifampin 600 mg", "type": "DRUG" }, { "name": "Rabeprazole 40 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hutchmed", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 59, "start_date": "2022-06-01", "completion_date": "2022-08-06", "has_results": false, "last_update_posted_date": "2024-03-06", "last_synced_at": "2026-11-15T01:12:18.773Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05602597" }, { "nct_id": "NCT00006350", "title": "Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "daclizumab", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2000-01", "completion_date": "2001-11", "has_results": false, "last_update_posted_date": "2019-11-04", "last_synced_at": "2026-11-15T01:12:18.773Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006350" }, { "nct_id": "NCT00004874", "title": "Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "tositumomab and iodine I 131 tositumomab", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "19 Years to 120 Years" }, "enrollment_count": 31, "start_date": "1998-11", "completion_date": "2012-11", "has_results": false, "last_update_posted_date": "2018-01-17", "last_synced_at": "2026-11-15T01:12:18.773Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004874" }, { "nct_id": "NCT06986174", "title": "A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Waldenström Macroglobulinemia", "Lymphoplasmacytic Lymphoma", "B-Cell Lymphoproliferative Disorder", "Indolent Lymphoma" ], "interventions": [ { "name": "Pacritinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shayna Sarosiek, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-11-21", "completion_date": "2032-10-01", "has_results": false, "last_update_posted_date": "2025-12-05", "last_synced_at": "2026-11-15T01:12:18.773Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06986174" }, { "nct_id": "NCT05192889", "title": "Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory Acute Lymphoblastic Leukemia", "Relapsed Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Navitoclax", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Calaspargase Pegol", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Intrathecal Triples", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Erwinia asparaginase", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "4 Years to 30 Years" }, "enrollment_count": 35, "start_date": "2022-08-25", "completion_date": "2027-02", "has_results": true, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-11-15T01:12:18.773Z", "location_count": 2, "location_summary": "New York, New York • Memphis, Tennessee", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05192889" }, { "nct_id": "NCT00087425", "title": "Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "bryostatin 1", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute on Aging (NIA)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2004-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-30", "last_synced_at": "2026-11-15T01:12:18.773Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00087425" }, { "nct_id": "NCT00006040", "title": "Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "etoposide", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "yttrium Y 90 monoclonal antibody M195", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-04", "completion_date": "2003-11", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-11-15T01:12:18.773Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006040" }, { "nct_id": "NCT06400225", "title": "Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "Ulixertinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2019-07-24", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-11-15T01:12:18.773Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06400225" } ] }